Clinical application of non-invasive prenatal testing using cell free fetal DNA
Journal of the Korean Medical Association
;
: 771-779, 2014.
Artículo
en Coreano
| WPRIM
| ID: wpr-51688
ABSTRACT
Non-invasive prenatal testing using next generation sequencing technology with cell free fetal DNA from the blood of pregnant women has been rapidly adopted as a screening test for the detection of disorders involving chromosomal aneuploidy, especially Down syndrome. However as part of a prenatal recommendation in high-risk group, this laboratory assessment should be accompanied by informed counseling at both pre-test and post-test stages. In low-risk group and multifetal pregnancies, only conventional maternal serum screening tests in the first trimester and/or second trimester in addition to measurement of nuchal translucency should be recommended, until this potential tool has been incorporated into current screening strategic modalities on the basis ofsufficient published data.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Segundo Trimestre del Embarazo
/
Primer Trimestre del Embarazo
/
ADN
/
Tamizaje Masivo
/
Síndrome de Down
/
Consejo
/
Mujeres Embarazadas
/
Medida de Translucencia Nucal
/
Pruebas de Detección del Suero Materno
/
Aneuploidia
Tipo de estudio:
Estudio de tamizaje
Límite:
Femenino
/
Humanos
/
Embarazo
Idioma:
Coreano
Revista:
Journal of the Korean Medical Association
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS